Abstract
Dermatomyositis (DM) is a rare chronic idiopathic inflammatory myopathy (IIM), characterized by symmetrical proximal muscle involvement and typical cutaneous lesions. The incidence is approximately 5/1000000 population. DM occurs in all races, twice more often in females. It is also not rare in childhood (juvenile DM or JDM). In about 10% of patients the cutaneous changes characteristic of DM are not associated with muscle disease (amyopathic DM). DM of adults is associated in about 30% of patients with internal malignancies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Further reading
Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillary studies in the diagnosis of connective tissue diseases. Clin Rheumatol 1996; 15: 148–53.
Dalakas MC et al A controlled trial of high-dose intravenous immune globulin influsions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000.
Ghate J, Katsambas A, Augerinou G, Jorizzo JL. A therapeutic update on dermatomyositis/polymyositis. Int J Dermatol 2000; 39: 81–7.
Huber AM, Lag B, Le Blanc CMA et al Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541–9.
Jablonska S, Chorzelski TP, Blaszczyk M, JarzabekChorzelska M, Kumar V, Beutner EH. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 1993; 10: 457–72.
Joffe MM, Love LA, Leff RI et al Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisolane, azathioprine and methotrexate and a comparison of their efficacy. Am JMed 1993; 94: 379–87.
Kastler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997; 36: 67–71.
Mattheou-Vakeli G, Ioannides D, Lazaridou E, Kalabalikis D, Batsios P, Minas A. Dermatomyositis sine myositis in five cases. J Eur Acad Dermatol Venereol 1997; 8: 208–11.
Pachman LM. Polymyositis and dermatomyositis in children. In: Maddison PJ, Isenberg D, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology, 2nd edn. Oxford: Oxford University Press, 1998: 1287–300.
Park JH et al Muscle abnormalities in juvenile dermatomyositis patients. Arthritis Rheum 2000; 43: 2359–67.
Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36: 319–24.
Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporine therapy in refractory juvenile dermatomyositis. Experience and long term follow-up of 6 cases. JRheumatol 1996; 23: 1424–7.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Jablonska, S., Blaszczyk, M. (2003). Dermatomyositis. In: Katsambas, A.D., Lotti, T.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-07131-1_21
Download citation
DOI: https://doi.org/10.1007/978-3-662-07131-1_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-05657-4
Online ISBN: 978-3-662-07131-1
eBook Packages: Springer Book Archive